We offer world-leading contract development and manufacturing organization (CDMO) services for biologics, vaccines, and advanced therapies with production facilities in the United States, Europe, and Japan. Our end-to-end CDMO services are designed to support the development of biopharmaceuticals from preclinical to commercial launch. Our integrated solutions combine scientific expertise, regulatory insights, and advanced manufacturing capabilities to accelerate timelines, ensure compliance, and drive success.
As a trusted partner for life, we give our customers everything they need to develop and commercialize treatments and therapies effectively and efficiently to improve patients' lives.
Over 30 years of industry-leading experience
Offering fully integrated CDMO services tailored to the development and manufacturing of lipid nanoparticles (LNPs), liposomes, and mRNA-based therapeutics
Planning to provide high-quality and high-speed services for ADCs from 2027, a market that is rapidly expanding and diversifying
Offering innovative development and manufacturing services from early development to commercial market supply, and from drug substance to drug product across a variety of cell types
We work in strategic partnership with biopharmaceutical and biotech companies to develop and manufacture the latest in biologics, advanced therapies, and vaccines. Our solutions bridge the gap between drug discovery and commercial supply — helping to bring life-impacting treatments to patients every day.
In June 2025, FUJIFILM Diosynth Biotechnologies became FUJIFILM Biotechnologies, serving global partners seeking CDMO services from preclinical to clinical to approval, launch and commercialization across all modalities and scales.
Our technology enables the creation of human induced pluripotent stem cells (iPSCs) from anyone, starting with a standard blood draw. Meanwhile, our proprietary manufacturing system and cGMP capabilities enable large-scale production of a range of cell types with high reproducibility for research use, and some for therapeutic use, including cardiac, neural hematopoietic, hepatic, and other cells.
We are focused on the CDMO business for new modalities and the discovery support CRO business. We license our proprietary ionizable lipids designed for in vivo/ex vivo nucleic acid delivery with enhanced bioavailability. We also offer services to accelerate client drug discovery / development processes as well as our work to develop medicines for drug-resistant bacterial infections. FUJIFILM Pharmaceuticals USA is a marketing partner of FUJIFILM Toyama Chemical.